Irish low-cost airline Ryan Air confirmed last Friday that it would take over Austrian airline Niki, which went bankrupt last week. The Irish company said it had contacted Niki’s management commissioners to discuss the bankruptcy of the Austrian company and the possible acquisition of the remaining assets. Nicky Lauda, a former Austrian airline and former racing champion, said yesterday that he was considering to buy the company, which stopped flights yesterday after failing to sell it to Lufthansa. In the last months, Lauda also hinted that he is interested in buying back the low-cost airline he founded in 2003 and then sold it to German Air Berlin in 2011, which also went bankrupt earlier this year.
German car maker Daimler Chrysler has come to the agreement to buy a majority stake in France’s Chauffer-Drive, a rival of Uber’s revolutionary taxi booking system. The agreement was announced in a joint statement by the two companies, but the acquisition price remained undisclosed, so far.
Founded in 2011, Chauffeur Drive has more than 1.5 million customers and employs around 18,000 drivers, being fairly used in Paris. Traditional automakers around the world are testing the best ways to work with various new technologies from electric cars to self-driving vehicles, which require huge investments and have turned companies such as Google and Tesla into rivals. Daimler has already joined the growing market of ride sharing companies.
The famous Swiss pharmaceutical company Roche has announced on last Friday that it would buy US drug company Ignyta for $1.7 billion, gaining access and boosting the production of a range of experimental cancer drugs.
Roche will allegedly bid $27 per share in Ignatia, 74% more from last week’s closing price, according to a statement from San Diego based Ignyta. The company develops products used to diagnose and treat specific cancers caused by rare genetic mutations. The agreement with Ignyta comes from Roche’s strategy to provide appropriate medicine to those in need, and allows them to expand and strengthen their oncology portfolio worldwide, the Swiss chief executive said.